Endocrine Abstracts

Introduction: Glucocroticoids (GCs) which are routinely used in the treatment of Acute Lymphocytic Leukemia (ALL), found recently to be beneficial in a subset of AML patients resistant to chemotherapy, by promoting leukemia cells apoptosis. Current studies indicate that vitamin D (VitD) deficiency is highly prevalent among AML patients, posing vitamin D as a therapeutic supplementation. Our previous study demonstrated that VitD exerts inhibitory effect on Dexamethasone-induced...

Objective: Intriguing studies suggest that osteocalcin (OC) and its carboxylated (Gla)/uncarboxylated form are involved in the regulation of insulin secretion and action. Additionally, advanced glycated end products (AGEs), directly regulate the secretion of these osteoblast derived molecules. In PCOS among the pathophysiological aberrations, deregulation of insulin secretion and action as well as elevated AGEs levels have been demonstrated. In this study, we evaluated the ser...

IntroductionEndometriosis is a dysplastic disease affecting approximately 7–10% of reproductive–aged women. It is defined as the presence of endometrial-like tissue outside the uterine cavity. Disruption of circadian rhythm in night shift worker has been associated with menstrual irregularity and increased chance of developing endometriosis and ovarian tumors. The central circadian clock system located in hypothalamic suprachiasmatic nucleus (...

Introduction: The biological rhythm pattern is synchronized through circadian oscillation of cortisol and melatonin release. Increased cortisol levels and circadian rhythm disruption act as an oncogenic factor in endometrial cancer through among others- dysregulation of cell proliferation/apoptosis and invasion.Aim: To investigate, whether there is an oscillatory expression of the clock genes, MT1 and GR expression in human endometrial carcinoma cells. T...

Introduction: Malnutrition in neonates and children has been associated with adult-onset diseases such as obesity and atherosclerosis. Infants breastfeeding exhibit a different pattern of orexin-α secretion compared to formula-fed or infants on parenteral feeding. Given the protective role of maternal milk in the onset of metabolic syndrome and atherosclerosis in later life, we hypothesized that orexin-α may be involved in this process. We studied in vitro t...

Introduction: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disorders. Endocan is a novel molecule of endothelial dysfuction which is expressed in liver. SGLT2i have been reported to improve NAFLD through amelioration of inflammation. While there are contradictory results regarding the serum endocan levels in NAFLD patients, data regarding endocan expression in liver tissue are limited. Aim: Herein, we aimed to investigat...

Background: Sodium glucose co-transporter 2 inhibitors reduce the incidence of cardiovascular events in patients with type 2 diabetes mellitus based on the results of recent cardiovascular outcome studies. Herein, we investigated the effects of long-term treatment with empagliflozin on biochemical and immunohistochemical markers related to atherosclerosis development in apolipoprotein E knockout [Apo-E(−/−)] mice.Methods: At the ag...

Introduction: Metabolic disorders characterized by insulin resistance/hyperinsulinemia, such as metabolic syndrome and T2DM, are associated with Non-Alcoholic Fatty Liver Disease (NAFLD). SGLT-2i reduce reabsorption of glucose from the kidneys thereby promoting glucosuria, while their beneficial effects on insulin resistance have been recently recognized. In this study, we aimed to investigate the effect of Empagliflozin, in de novo triglyceride synthesis and beta-oxi...

Introduction: Type 2 diabetes mellitus (T2DM) is characterized by progressive impairment/ loss of pancreatic beta cell function Activation of endoplasmic reticulum (ER) stress by glucose variation has been suggested as an essential step towards beta cell dysfunction. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are widely used in the treatment of T2DM considering their beneficial cardiometabolic sequalae. In the present study, we aimed to investigate the effect of Empag...

Sodium glucose co-transporter2 (SGLT2) inhibitors reduce the incidence of cardiovascular events in patients with Type 2 Diabetes Mellitus (T2DM) based on the results of recent cardiovascular outcome studies. Herein, we investigated the effects of long-term treatment with canagliflozin on biochemical and immunohistochemical markers related to atherosclerosis and atherosclerosis development in the aorta of Apolipoprotein E knockout (Apo-E(−/−)) mice. After...